Senti Biosciences Holdings, Inc. (SNTI) News
Follow Senti Biosciences Holdings, Inc. (SNTI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Brenda Cooperstone resigns from Senti Biosciences board and as Compensation Committee chair
Senti Biosciences accepted the resignation of Brenda Cooperstone, Ph.D. from the Board and as Chair of the Compensation Committee, effective immediately.Original SEC Filing: Senti Biosciences Holdings, Inc. [ SNTI ] - 8-
REGULATION | Sep 24, 2026, 08:15 PM UTC
L
Senti Biosciences raises $2 million convertible debt and $2.5 million equity commitment
Senti Biosciences announced $2.0 million senior secured convertible notes under its existing purchase agreement and documentation amended to add NSG. It also disclosed a $2.5 million equity commitment from an affiliate a
MNA | Sep 04, 2026, 10:14 AM UTC
L
Senti Biosciences gets Nasdaq noncompliance notice; trading continues
Senti Biosciences Holdings received Nasdaq notices for failing the $1.00 minimum bid price and $2.5 million stockholders’ equity requirements for the Nasdaq Capital Market. Trading continues under SNTI, with until Feb 23
EQUITY | Sep 02, 2026, 08:36 PM UTC
M
Senti Biosciences clears $2M third-tranche note sale to NSG
Senti Biosciences amended its Securities Purchase Agreement on September 1, 2026 to permit senior secured convertible notes in more than two tranches, authorizing a $2.0 million third-tranche issuance to NSG BioInnovatio
EQUITY | Sep 02, 2026, 08:36 PM UTC
L
SNTI Senti Biosciences - cvr milestones: $10M for BLA filing, $20M for FDA approval, $30M for $200M sales
SNTI Senti Biosciences - cvr milestones: $10M for BLA filing, $20M for FDA approval, $30M for $200M sales
REGULATION | Jul 15, 2026, 11:30 AM UTC